Merck has been one of the stronger performers in big pharma over the past few years, and with the stock recently around ...

Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a ...

Merck (MRK) closed at $113.87 in the latest trading session, marking a -1.36% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.09%. On the other hand, the Dow ...

A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European ...

The medicines Merck sells today grew at their usual pace. What investors spent the year repricing was everything that comes next.

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

The same overview notes that Barclays analyst Emily Field also holds Merck at a Hold rating, while DBS keeps a Buy rating on ...

Merck & Co., Inc. is fairly valued after a strong YTD rally, with momentum in Keytruda and Winrevair driving raised guidance. Keytruda's patent cliff in 2028 remains a pivotal risk, but MRK is ...

Merck & Co. stock (ISIN US58933Y1055) was trading at EUR 130.41 at Lang & Schwarz on October 9, 2026 at 8:10 p.m. CEST, up ...